Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PrimeGen Biotech and Unidym, a majority-owned subsidiary of Arrowhead Research, have announced a corporate alliance focused on exploring new applications for carbon nanotubes in stem cell medicine.
Subscribe to our email newsletter
Unidym brings to this partnership its leadership in carbon nanotube science, technology and production. PrimeGen will have access to Unidym’s extensive patent portfolio, services and industry standard Hipco carbon nanotubes. PrimeGen previously said that, researchers have, for the first time, successfully used non-viral technologies to reprogram adult human cells into stem cells that the company refers to as intermediate iPS cells.
Thomas Yuen, CEO of PrimeGen Biotech, said: “Our combined efforts will undoubtedly generate important advances in the field of regenerative medicine and bring us closer to the day when clinically safe and effective individualized stem cell therapies can be administered in a routine manner to patients.”